Back to top
more

Oramed Pharmaceuticals (ORMP)

(Delayed Data from NSDQ)

$2.30 USD

2.30
107,258

-0.07 (-2.95%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $2.29 -0.01 (-0.43%) 5:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Oramed Pharmaceuticals Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 162 156 146 94 40
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 1 1 2 1 1
Total Current Assets 163 157 148 95 41
Net Property & Equipment 1 1 0 0 0
Investments & Advances 56 3 29 32 4
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 221 162 178 128 45
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 51 0 0 0 0
Accounts Payable 2 4 5 4 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 1 3 3 3
Total Current Liabilities 53 6 7 7 5
Mortgages 0 0 0 0 0
Deferred Taxes/Income 4 4 3 4 7
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 58 10 11 11 12
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 321 314 293 230 125
Retained Earnings -158 -163 -127 -115 -93
Other Equity -1 -1 0 1 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 163 151 167 117 33
Total Liabilities & Shareholder's Equity 221 162 178 128 45
Total Common Equity 163 151 167 117 33
Shares Outstanding 40.30 39.10 38.20 26.60 17.70
Book Value Per Share 4.04 3.87 4.36 4.38 1.86

Fiscal Year End for Oramed Pharmaceuticals Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 162 175 150 154
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 1 1 1 1
Total Current Assets NA 163 176 151 155
Net Property & Equipment NA 1 1 1 1
Investments & Advances NA 56 53 4 3
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 221 231 156 160
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 51 75 0 0
Accounts Payable NA 2 3 1 4
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 1
Total Current Liabilities NA 53 78 1 5
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 4 4 4 4
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 58 83 6 10
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 321 320 319 317
Retained Earnings NA -158 -171 -168 -166
Other Equity NA -1 -1 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 163 148 151 150
Total Liabilities & Shareholder's Equity NA 221 231 156 160
Total Common Equity 0 163 148 151 150
Shares Outstanding 40.50 40.30 40.20 40.00 39.70
Book Value Per Share 0.00 4.04 3.69 3.77 3.78